Experimental Simulation in Ophthalmology as a Basis for the Development of New Ways to Prevent Blindness and Low Vision in Premature Infants: Literature Review
https://doi.org/10.15690/pf.v22i2.2869
Abstract
The literature review summarizes the results of a long-term experimental study of the pathogenesis of retinopathy of prematurity in a rat model conducted at the National Medical Research Center for Eye Diseases named after Helmholtz, as well as data from foreign authors who are the basis for finding ways to prevent the development of this disease with medication.
Keywords
Supporting agencies: Not specified
About the Authors
Lyudmila A. Katargina
National Medical Research Center for Eye Diseases named after Helmholtz
Russian Federation
Disclosure of interest:
Russian Federation
Lyudmila A. Katargina - MD, PhD, Professor.
Moscow
Disclosure of interest:
Not declared
Tatiana A. Pavlenko
National Medical Research Center for Eye Diseases named after Helmholtz
Russian Federation
Disclosure of interest:
Russian Federation
Tatyana А. Pavlenko, MD, PhD.
Moscow
Disclosure of interest:
Not declared
Olga V. Beznos
National Medical Research Center for Eye Diseases named after Helmholtz
Russian Federation
Disclosure of interest:
Russian Federation
Olga V. Beznos - MD.
Moscow
Disclosure of interest:
Not declared
Natalya A. Osipova
National Medical Research Center for Eye Diseases named after Helmholtz
Russian Federation
Disclosure of interest:
Russian Federation
Natalya A. Osipova - MD, PhD.
14/19, Sadovaya Chernogryazskaya Str., Moscow, 105062
Disclosure of interest:
Not declared
Anna Yu. Panova
National Medical Research Center for Eye Diseases named after Helmholtz
Russian Federation
Disclosure of interest:
Russian Federation
Anna Yu. Panova - MD, PhD.
Moscow
Disclosure of interest:
Not declared
References
1. Quinn G. Retinopathy of prematurity blindness worldwide: phenotypes in the third epidemic. Eye Brain. 2016;8:31–36. doi: https://doi.org/10.2147/EB.S94436
2. Dammann O, Hartnett ME, Stahl A. Retinopathy of prematurity. Dev Med Child Neurol. 2023;65(5):625–631. doi: https://doi.org/10.1111/dmcn.15468
3. Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol. 1954;38(7):397–432. doi: https://doi.org/10.1136/bjo.38.7.397
4. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res. 2010;29(6):500– 519. doi: https://doi.org/10.1016/j.preteyeres.2010.05.003
5. Katargina LA, Osipova NA. The basic strategy of development an animal model of retinopathy of prematurity. Rossiyskaya pediatricheskaya oftal’mologiya = Russian Pediatric Ophthalmology. 2014;7(1):56–60. (In Russ). doi: https://doi.org/10.17816/rpoj37602]
6. Katargina LA, Chesnokova NB, Beznos OV, et al. An experimental Study of the Pathogenesis of Retinopathy of Prematurity as a Promising Direction of Search for New Medicinal Approaches to its Prevention and Treatment. Russian Ophthalmological Journal. 2016;9(1):68–72. (In Russ). doi: https://doi.org/10.21516/2072-0076-2016-9-1-68-72]
7. Katargina LA, Khoroshilova-Maslova IP, Maybogin MA, et al. Pathomorphological features of the development of experimental retinopathy of prematurity. International Journal of Applied and Fundamental Research. 2017;3(2):190–194. (In Russ). doi: https://doi.org/10.17513/mjpfi.11424]
8. Chen J, Stahl A, Hellstrom A, Smith LE. Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr. 2011;23(2):173–178. doi: https://doi.org/10.1097/MOP.0b013e3283423f35
9. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res. 2004;14(Suppl. А):140–144. doi: https://doi.org/10.1016/j.ghir.2004.03.030
10. Hartnett ME, Penn JS. Mechanisms and Management of Retinopathy of Prematurity. N Engl J Med. 2012;367(26):2515–2526. doi: https://doi.org/10.1056/NEJMra1208129
11. Katargina LA, Denisova EV, Osipova NA, Panova AYu. The role of monoamines in regulation of angiogenesis and prospects of their application in retinopathy of prematurity. Rossiyskaya pediatricheskaya oftal’mologiya = Russian pediatric ophthalmology. 2018;13(2):76–80. (In Russ). doi: https://doi.org/10.18821/1993-1859-2018-13-2-76-80
12. Chakroborty D, Sarkar C, Yu H, et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci U S A. 2011;108(51):20730–20735. doi: https://doi.org/10.1073/pnas.1108696108
13. Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol. 2010;6(12):1863–1881. doi: https://doi.org/10.2217/fon.10.142
14. Dvorak HF. Angiogenesis: update 2005. J Thromb Haemost. 2005;3(8):1835–1842. doi: https://doi.org/10.1111/j.15387836.2005.01361.x
15. Dal Monte M, Cammalleri M, Mattei E, et al. Protective effects of β1/2 adrenergic receptor deletion in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2015;56(1):59–73. doi: https://doi.org/10.1167/iovs.14-15263
16. Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factorand inflammation-related pathways. Lab Invest. 2002;82(6):747– 756. doi: https://doi.org/10.1097/01.lab.0000017372.76297.eb
17. Wilkinson-Berka JL, Rana I, Armani R, Agrotis A. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin Sci (Lond). 2013;124(10):597–615. doi: https://doi.org/10.1042/CS20120212
18. Ola MS, Alhomida AS, Ferrario CM, Ahmad S. Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-(1-12) Axis in the Pathogenesis of Diabetic Retinopathy. Curr Med Chem. 2017;24(28):3104–3114. doi: https://doi.org/10.2174/0929867324666170407141955
19. Katargina LA, Khoroshilova-Maslova IP, Bondarenko NS, et al. Angiogenic properties of catecholamines from the viewpoint of the pathogenesis of retinopathy of prematurity. Russian Ophthalmological Journal. 2018;11(4):49–54. (In Russ). doi: https://doi.org/10.21516/2072-0076-2018-11-4-49-54]
20. Katargina LA, Osipova NA, Panova AYu, et al. The role of catecholamines in the development of pathological neovascularization of the retina in an experimental model of retinopathy of prematurity in rats. Proceedings of the Academy of Sciences. 2019;489(3):313–317. (In Russ). doi: https://doi.org/10.1134/S160767291906005X
21. Katargina LА, Osipova NА, Panova АY, et al. Prognostic value estimation of monoamines systemic level in retinopathy of prematurity in experiment. Sovremennye tehnologii v medicine. 2021;13(3):41–46. (In Russ). doi: https://doi.org/10.17691/stm2021.13.3.05
22. Katargina LA, Chesnokova NB, Beznos OV, et al. Angiotensin-II as a Trigger Factor in the Development of Retinopathy of Prematurity. Ophthalmology in Russia. 2020;17(4):746–751. (In Russ). doi: https://doi.org/10.18008/1816-5095-2020-4-746-751
23. Katargina LA, Chesnokova NB, Pavlenko TA, et al. Enalaprilat as a new means of preventing the development of retinopathy of prematurity. Biomeditsinskaya Khimiya. 2023;69(2):97–103 (In Russ). doi: https://doi.org/10.18097/PBMC20236902097
24. Dal Monte M, Martini D, Latina V, et al. Beta-adrenoreceptor (b-AR) agonism influences retinal responses to hypoxia in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2012;53(4):2181–2192. doi: https://doi.org/10.1167/iovs.11-9408
25. Ricci B, Ricci F, Maggiano N. Oxygen-induced retinopathy in the newborn rat: morphological and immunohistological findings in animals treated with topical timolol maleate. Ophthalmologica. 2000;214(2):136–139. doi: https://doi.org/10.1159/000027483
26. Kaempfen S, Neumann RP, Jost K, Schulzke SM. Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev. 2018;3(3):CD011893. doi: https://doi.org/10.1002/14651858.CD011893
27. Stritzke A, Kabra N, Kaur S, et al. Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and metaanalysis. J Perinatol. 2019;39(12):1584–1594. doi: https://doi.org/10.1038/s41372-019-0503-x
28. Kong HB, Zheng GY, He BM, et al. Clinical efficacy and safety of propranolol in the prevention and treatment of retinopathy of prematurity: a meta-analysis of randomized controlled trials. Front Pediatr. 2021;9:631673. doi: https://doi.org/10.3389/fped.2021.631673
29. Shafique MA, Haseeb A, Uddin MMN, et al. Effectiveness of propranolol in preventing severe retinopathy of prematurity: a comprehensive systematic review and meta-analysis. Am J Ophthalmol. 2023;259:141–50. doi: https://doi.org/10.1016/j.ajo.2023.11.012
30. Filippi L, Cavallaro G, Bagnoli P, et al. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013;163(6):1570–1577.e6. doi: https://doi.org/10.1016/j.jpeds.2013.07.049
31. Filippi L, Cavallaro G, Bagnoli P, et al. Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial. Pediatr Res. 2017;81(2):307–314. doi: https://doi.org/10.1038/pr.2016.230
32. Filippi L, Cavallaro G, Berti E, et al. Propranolol 0.2% eye micro-drops for retinopathy of prematurity: a prospective phase IIB study. Front Pediatr. 2019;7:180. doi: https://doi.org/10.3389/fped.2019.00180
Review
For citations:
Katargina L.A., Pavlenko T.A., Beznos O.V., Osipova N.A., Panova A.Yu. Experimental Simulation in Ophthalmology as a Basis for the Development of New Ways to Prevent Blindness and Low Vision in Premature Infants: Literature Review. Pediatric pharmacology. 2025;22(2):141-146. (In Russ.) https://doi.org/10.15690/pf.v22i2.2869
Views:
104
Email this article 